Provided by Tiger Trade Technology Pte. Ltd.

ProMIS Neurosciences Inc

14.74
-0.3900-2.58%
Post-market: 14.740.00000.00%19:39 EDT
Volume:31.68K
Turnover:468.78K
Market Cap:132.18M
PE:-0.65
High:15.34
Open:14.79
Low:14.26
Close:15.13
52wk High:39.75
52wk Low:6.27
Shares:8.97M
Float Shares:1.02M
Volume Ratio:1.69
T/O Rate:3.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-22.6100
EPS(LYR):-22.6100
ROE:-521.61%
ROA:-178.72%
PB:-105.03
PE(LYR):-0.65

Loading ...

Fact Check: North Natuna Sea Was Not Used as Collateral for the Whoosh Rail Project

Tempo
·
Jan 16

BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial

Reuters
·
Dec 18, 2025

ProMIS Neurosciences Completes Enrollment for Phase 1b Trial of PMN310 in Alzheimer’s Disease

Reuters
·
Dec 18, 2025

ProMIS Neurosciences Inc - Interim Analysis Expected in Q2 2026, Final Results in Q4 2026

THOMSON REUTERS
·
Dec 18, 2025

ProMIS Neurosciences Exceeds Target Enrollment in Precise-Ad Phase 1B Clinical Trial of Pmn310 in Alzheimer’s Disease

THOMSON REUTERS
·
Dec 18, 2025

ProMIS Neurosciences Advances PMN310 Alzheimer’s Trial With Interim Results Expected in 2026

Reuters
·
Dec 10, 2025

ProMIS Neurosciences Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 02, 2025

BRIEF-Plasma pTau Identified as Key Early Endpoint in Alzheimer's Research

Reuters
·
Dec 01, 2025

ProMIS Neurosciences Announces Interim Phase 1b Trial Readout for PMN310 in Alzheimer's Disease Set for Q2 2026

Reuters
·
Dec 01, 2025

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma Ptau as a Predictive Early Endpoint in Alzheimer’s Trials, Supporting Its Ongoing Phase 1B Precise-Ad Trial With Pmn310

THOMSON REUTERS
·
Dec 01, 2025

ProMIS Neurosciences CEO to Join Fireside Chat at Evercore Healthcare Conference

Reuters
·
Dec 01, 2025

NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM

Reuters
·
Nov 27, 2025

Promis Neurosciences Inc trading halted, news pending

TIPRANKS
·
Nov 27, 2025

Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Crispr Therapeutics AG (CRSP)

TIPRANKS
·
Nov 26, 2025

Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher

Benzinga
·
Nov 24, 2025

ProMIS Neurosciences Announces 1-for-25 Reverse Stock Split

Reuters
·
Nov 24, 2025

ProMIS Neurosciences Announces Reverse Stock Split

THOMSON REUTERS
·
Nov 24, 2025

ProMIS Neurosciences Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
Nov 21, 2025

PTS Announces Official Launch of PMN on Republic -- Japan's First Compliant STO Offered in the United States

prnewswire
·
Nov 21, 2025

ProMIS Neurosciences Inc. held special shareholder meeting

Reuters
·
Nov 19, 2025